Patient 6 had metastatic HCC with an emergent pathogenic CHEK2 mutation for which the patient was initiated on olaparib as prior studies have shown that cancers, particularly of the prostate, with DNA repair defects may be sensitive to poly adenosine diphosphate-ribose polymerase inhibitors37. This evidence concerns the gene CHEK2 and hepatocellular carcinoma.